Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Illumina ( (ILMN) ).
On November 10, 2025, Illumina, Inc. announced it had entered into an Underwriting Agreement with Goldman Sachs & Co. LLC and BofA Securities, Inc. for the issuance and sale of $500 million in notes due 2030. The proceeds from this offering are expected to be used for general corporate purposes, including the repayment of existing notes and the acquisition of SomaLogic, Inc. This strategic financial move is likely to impact Illumina’s operations and market positioning by potentially enhancing its financial flexibility and supporting its expansion plans.
The most recent analyst rating on (ILMN) stock is a Buy with a $195.00 price target. To see the full list of analyst forecasts on Illumina stock, see the ILMN Stock Forecast page.
Spark’s Take on ILMN Stock
According to Spark, TipRanks’ AI Analyst, ILMN is a Outperform.
Illumina’s strong performance in the earnings call and bullish technical indicators are the most significant factors driving the score. Financial performance shows recovery but is tempered by increased leverage and cash flow challenges. Valuation is reasonable, supporting a positive outlook.
To see Spark’s full report on ILMN stock, click here.
More about Illumina
Illumina, Inc. operates in the biotechnology industry, specializing in the development and manufacturing of integrated systems for the analysis of genetic variation and function. The company focuses on providing innovative sequencing and array-based solutions for genetic analysis, serving a wide range of markets including research, clinical, and applied markets.
Average Trading Volume: 1,687,306
Technical Sentiment Signal: Buy
Current Market Cap: $18.6B
Learn more about ILMN stock on TipRanks’ Stock Analysis page.